FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020671419> ?p ?o ?g. }

• W2020671419 endingPage "721" @default.
• W2020671419 startingPage "721" @default.
• W2020671419 abstract "Editorials15 May 1990Zidovudine for Early Human Immunodeficiency Virus (HIV) Infection: Who, When, and How?John Ruedy, MD, Martin Schechter, MD, Julio S. G. Montaner, MDJohn Ruedy, MDSearch for more papers by this author, Martin Schechter, MDSearch for more papers by this author, Julio S. G. Montaner, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-10-721 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince it was originally described in 1981, the acquired immunodeficiency syndrome (AIDS) has been a complex therapeutic challenge. In 1983, the discovery of human immunodeficiency virus type 1 (HIV) as the causative agent of AIDS opened the door for the rational development of specific therapeutic agents. To date, only one such agent, zidovudine (also known as azidothymidine, or AZT) has been definitively shown to alter the usually rapidly fatal course of AIDS (1, 2). Results of a number of recently concluded trials, some of them still unpublished, in patients at earlier stages of HIV infection necessitate a reassessment of our...References1. FischlRichmanGrieco MDM. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med. 1987;317:185-91. CrossrefMedlineGoogle Scholar2. Creagh-KirkDoiAndrews TPE. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA. 1988;260:3009-15. CrossrefMedlineGoogle Scholar3. YarchoanThomasGrafman RRJ. Long-term administration of 3′-azido-2′,3′-dideoxythymidine to patients with AIDS-related neurological disease. Ann Neurol. 1988;23(Suppl):S82-7. CrossrefMedlineGoogle Scholar4. SchmittBigleyMcKinnis FJR. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988;319:1573-8. CrossrefMedlineGoogle Scholar5. MontanerLeFanning JTM. The effect of zidovudine on platelet counts in HIV-infected individuals. J Acquir Immune Defic Synd. 1990;3:[In press]. MedlineGoogle Scholar6. Zidovudine for the treatment of thrombocytopenia associated with human immunodeficiency virus (HIV). A prospective study. The Swiss Group for Clinical Studies on the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med. 1988;109:718-21. LinkGoogle Scholar7. LaneFalloonWalker HJR. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial. Ann Intern Med. 1989;111:41-50. LinkGoogle Scholar8. FischlRichmanHansen MDN. The safety and efficacy of zidovudine (AZT) in the treatment of patients with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med. 1990;112:727-37. LinkGoogle Scholar9. VolberdingLagakosKoch PSM. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-9. CrossrefMedlineGoogle Scholar10. RichmanFischlGrieco DMM. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192-7. CrossrefMedlineGoogle Scholar11. LarderDarbyRichman BCD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-4. CrossrefMedlineGoogle Scholar12. RookeTremblaySoudeyns RMH. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS. 1989;3:411-5. CrossrefMedlineGoogle Scholar13. LangPerkinsAnderson WHR. Patterns of T lymphocyte changes from human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr. 1989;2:63-9. MedlineGoogle Scholar14. de WolfLangeHouweling FJJ. Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis. 1988;158:615-22. CrossrefMedlineGoogle Scholar15. Moss A. Predicting who will progress to AIDS. Br Med J. 1988;297:1067-8. CrossrefMedlineGoogle Scholar16. SchechterCraibLe MKT. Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS. 1989;3:347-53. CrossrefMedlineGoogle Scholar17. KleckerCollinsYarchoan RJR. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987;41:407-12. CrossrefMedlineGoogle Scholar18. AvramisMarksonGomperts VWE. Biochemical pharmacology of AZT in human T-lymphoblastoid cells (CEM). Proceedings from the Fifth International Conference on AIDS. 1989;C-593:657. Google Scholar19. GelmonMontanerFanning KJM. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS. 1989;3:555-61. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byNeurocognitive Effects of Zidovudine and 2?,3?-Dideoxyinosine During the Treatment of Asymptomatic and Symptomatic HIV-1 Seropositive Patients. Comparison with Non-Treated PatientsA model for treatment strategy in the chemotherapy of AIDSIn HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabineMarkers predicting progression of human immunodeficiency virus-related diseaseA Study of the Safety and Survival of the Adoptive Transfer of Genetically Marked Syngeneic Lymphocytes in HIV-infected Identical TwinsThe ethics of HIV testing by physiciansZidovudine: Five Years LaterGavin X. McLeod, MD, Scott M. Hammer, MDInpatient morbidity among HIV-infected male soldiers prior to their diagnosis of HIV infection.AIDS, Nutrition, and InfectionBarry S. Renaler, PhDCompliance with Zidovudine TherapyLee B. Reichman, MD, MPH 15 May 1990Volume 112, Issue 10Page: 721-723KeywordsAIDSAzidothymidineHIVHIV infectionsHIV-1 Issue Published: 15 May 1990 PDF downloadLoading ..." @default.
• W2020671419 created "2016-06-24" @default.
• W2020671419 creator A5035215851 @default.
• W2020671419 creator A5073167350 @default.
• W2020671419 creator A5074441717 @default.
• W2020671419 date "1990-05-15" @default.
• W2020671419 modified "2023-09-23" @default.
• W2020671419 title "Zidovudine for Early Human Immunodeficiency Virus (HIV) Infection: Who, When, and How?" @default.
• W2020671419 cites W1968896603 @default.
• W2020671419 cites W1996640465 @default.
• W2020671419 cites W2009226722 @default.
• W2020671419 cites W2048706882 @default.
• W2020671419 cites W2067417470 @default.
• W2020671419 cites W2082266431 @default.
• W2020671419 cites W2086462809 @default.
• W2020671419 cites W2097538270 @default.
• W2020671419 cites W2111632718 @default.
• W2020671419 cites W2130594297 @default.
• W2020671419 cites W2160871721 @default.
• W2020671419 cites W2333399282 @default.
• W2020671419 cites W2340058544 @default.
• W2020671419 doi "https://doi.org/10.7326/0003-4819-112-10-721" @default.
• W2020671419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1970465" @default.
• W2020671419 hasPublicationYear "1990" @default.
• W2020671419 type Work @default.
• W2020671419 sameAs 2020671419 @default.
• W2020671419 citedByCount "15" @default.
• W2020671419 crossrefType "journal-article" @default.
• W2020671419 hasAuthorship W2020671419A5035215851 @default.
• W2020671419 hasAuthorship W2020671419A5073167350 @default.
• W2020671419 hasAuthorship W2020671419A5074441717 @default.
• W2020671419 hasConcept C126322002 @default.
• W2020671419 hasConcept C159047783 @default.
• W2020671419 hasConcept C203014093 @default.
• W2020671419 hasConcept C2779127605 @default.
• W2020671419 hasConcept C2779134260 @default.
• W2020671419 hasConcept C2780216070 @default.
• W2020671419 hasConcept C2780727368 @default.
• W2020671419 hasConcept C3013748606 @default.
• W2020671419 hasConcept C535046627 @default.
• W2020671419 hasConcept C71924100 @default.
• W2020671419 hasConceptScore W2020671419C126322002 @default.
• W2020671419 hasConceptScore W2020671419C159047783 @default.
• W2020671419 hasConceptScore W2020671419C203014093 @default.
• W2020671419 hasConceptScore W2020671419C2779127605 @default.
• W2020671419 hasConceptScore W2020671419C2779134260 @default.
• W2020671419 hasConceptScore W2020671419C2780216070 @default.
• W2020671419 hasConceptScore W2020671419C2780727368 @default.
• W2020671419 hasConceptScore W2020671419C3013748606 @default.
• W2020671419 hasConceptScore W2020671419C535046627 @default.
• W2020671419 hasConceptScore W2020671419C71924100 @default.
• W2020671419 hasIssue "10" @default.
• W2020671419 hasLocation W20206714191 @default.
• W2020671419 hasLocation W20206714192 @default.
• W2020671419 hasOpenAccess W2020671419 @default.
• W2020671419 hasPrimaryLocation W20206714191 @default.
• W2020671419 hasRelatedWork W1999388526 @default.
• W2020671419 hasRelatedWork W2010288878 @default.
• W2020671419 hasRelatedWork W2055733835 @default.
• W2020671419 hasRelatedWork W2064576269 @default.
• W2020671419 hasRelatedWork W2066920818 @default.
• W2020671419 hasRelatedWork W2120267205 @default.
• W2020671419 hasRelatedWork W2135124387 @default.
• W2020671419 hasRelatedWork W2313400264 @default.
• W2020671419 hasRelatedWork W2442654169 @default.
• W2020671419 hasRelatedWork W4253768777 @default.
• W2020671419 hasVolume "112" @default.
• W2020671419 isParatext "false" @default.
• W2020671419 isRetracted "false" @default.
• W2020671419 magId "2020671419" @default.
• W2020671419 workType "article" @default.